GLPwatch
Papers (9189)
Page 84 of 154, ranked by citation count.
- Dulaglutide for the treatment of type 2 diabetes.
- Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.
- Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database.
- PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats.
- Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
- Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.
- Mouse insulin cells expressing an inducible RIPCre transgene are functionally impaired.
- Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.
- Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
- Change in HbA<sub>1c</sub> Across the Baseline HbA<sub>1c</sub> Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.
- A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.
- Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets.
- Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice.
- [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
- Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.
- Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
- A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
- Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
- Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.
- Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
- Immunotherapies in diabetes mellitus type 1.
- Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
- Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.
- Hes3 is expressed in the adult pancreatic islet and regulates gene expression, cell growth, and insulin release.
- Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice.
- Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
- [Exendin-4 alleviates oxidative stress and liver fibrosis by activating Nrf2/HO-1 in streptozotocin-induced diabetic mice].
- Antihyperglycemic Medications and Cardiovascular Risk Reduction.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.
- A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.
- Functional enhancement of beta cells in transplanted pancreatic islets by secretion signal peptide-linked exendin-4 gene transduction.
- The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest.
- Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
- Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes.
- Nutrient Optimization Reduces Phosphorylation and Hydroxylation Level on an Fc-Fusion Protein in a CHO Fed-Batch Process.
- Proteomic analysis of INS-1 rat insulinoma cells: ER stress effects and the protective role of exenatide, a GLP-1 receptor agonist.
- C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.
- Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins.
- Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
- Oral Semaglutide Reduces HbA<sub>1c</sub> and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
- Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice.
- Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.
- Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.
- Local administration of high-dose diabetes medicine exendin-4 inhibits orthodontic tooth movement in mice.
- Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective.
- A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers.
- Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
- PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan.
- NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.
- Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
- Long-term treatment with EXf, a peptide analog of Exendin-4, improves β-cell function and survival in diabetic KKAy mice.
- Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study.
- Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
- Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity.
- GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.
- Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
- Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
- Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction.
- Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study.